{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:30:52Z","timestamp":1793997052847,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C64667\/A27958"],"award-info":[{"award-number":["C64667\/A27958"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Robot-assisted pelvic lymph node dissection (rPLND) has been reported in heterogenous groups of patients with melanoma, including macroscopic or at-high-risk-for microscopic metastasis. With changing indications for surgery in melanoma, and availability of effective systemic therapies, pelvic dissection is now performed for clinically detected bulky lymph node metastasis followed by adjuvant drug therapy. rPLND has not been compared with open pelvic lymph node dissection (oPLND) for modern practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All patients undergoing pelvic node dissection for macroscopic melanoma at a single institution were reviewed as a cohort, observational study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two pelvic lymph node dissections were identified (8 oPLND; 14 rPLND). The number of pelvic lymph nodes removed was similar (median oPLND 6.5 (interquartile range [IQR] 6.0\u201312.5] versus rPLND 6.0 [3.75\u20139.0]), with frequent matted nodes (11\/22, 50.0%). Operative time (median oPLND 130 min [IQR 95.5\u2013182] versus rPLND 126 min [IQR 97.8\u2013160]) and complications (Clavien-Dindo scale) were similar. Length of hospital stay (median 5.34 days (IQR 3.77\u20136.94) versus 1.98 days (IQR 1.39\u20133.50) and time to postoperative adjuvant therapy (median 11.6 weeks [IQR 10.6\u201318.5] versus 7.71 weeks [IQR 6.29\u201310.4]) were shorter in the rPLND group. No differences in pelvic lymph node recurrence (<jats:italic>p<\/jats:italic> = 0.984), distant metastatic recurrence (<jats:italic>p<\/jats:italic> = 0.678), or melanoma-specific survival (<jats:italic>p<\/jats:italic> = 0.655) were seen (median follow-up 21.1 months [rPLND] and 25.7 months [oPLND]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>rPLND is an effective way to remove bulky pelvic lymph nodes in melanoma, with a shorter recovery and reduced interval to initiating adjuvant therapy compared with oPLND. This group of patients may especially benefit from neoadjuvant systemic approaches to management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14834-0","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T20:02:19Z","timestamp":1704398539000},"page":"2727-2736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Robot-Assisted Pelvic Dissection for Enlarged Lymph Nodes in Melanoma Improves Recovery with Equivalent Oncological Outcomes to Open Pelvic Dissection"],"prefix":"10.1245","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-2759","authenticated-orcid":false,"given":"Amit","family":"Roshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-0774","authenticated-orcid":false,"given":"Suzanne","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-122X","authenticated-orcid":false,"given":"Benjamin","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-893X","authenticated-orcid":false,"given":"Benjamin W.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6105-258X","authenticated-orcid":false,"given":"Amer J.","family":"Durrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh J. K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"32","key":"14834_CR1","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.18.02306","volume":"37","author":"U Leiter","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C, et al. Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol. 2019;37(32):3000\u20138. https:\/\/doi.org\/10.1200\/JCO.18.02306.","journal-title":"J Clin Oncol."},{"issue":"23","key":"14834_CR2","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"N Engl J Med."},{"key":"14834_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines Melanoma: Cutaneous v3.2023. Published 2023. Accessed 28 Nov 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1492."},{"key":"14834_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005493","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med."},{"issue":"17","key":"14834_CR5","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"14834_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200214","volume":"1","author":"AMM Eggermont","year":"2022","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1(11):1\u201312. https:\/\/doi.org\/10.1056\/EVIDoa2200214.","journal-title":"NEJM Evid."},{"issue":"3","key":"14834_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","volume":"12","author":"KF Grossmann","year":"2022","unstructured":"Grossmann KF, Othus M, Patel SP, et al. Adjuvant Pembrolizumab versus IFN\u03b12b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022;12(3):644\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1141.","journal-title":"Cancer Discov."},{"key":"14834_CR8","unstructured":"National Institute for Health and Care Excellence. NG 14 Melanoma: Assessment and Management (2022 Update); 2022."},{"issue":"1","key":"14834_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1245\/s10434-019-07333-8","volume":"27","author":"JT Miura","year":"2020","unstructured":"Miura JT, Dossett LA, Thapa R, et al. Robotic-assisted pelvic lymphadenectomy for metastatic melanoma results in durable oncologic outcomes. Ann Surg Oncol. 2020;27(1):196\u2013202. https:\/\/doi.org\/10.1245\/s10434-019-07333-8.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"14834_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/codi.15570","volume":"23","author":"JC Kong","year":"2021","unstructured":"Kong JC, Fisher SB, Bednarski BK. Robotic external iliac, deep inguinal and obturator lymph node dissection for Stage III melanoma\u2014a video vignette. Color Dis. 2021;23(5):1281\u20132. https:\/\/doi.org\/10.1111\/codi.15570.","journal-title":"Color Dis."},{"issue":"4","key":"14834_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rcs.2391","volume":"18","author":"E Francone","year":"2022","unstructured":"Francone E, Reina S, Spagnolo F, Di Maira L, Cafiero F, Solari N. Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: surgical technique and preliminary results. Int J Med Robot Comput Assist Surg. 2022;18(4):1\u20136. https:\/\/doi.org\/10.1002\/rcs.2391.","journal-title":"Int J Med Robot Comput Assist Surg."},{"issue":"2","key":"14834_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11701-014-0457-0","volume":"8","author":"A Pellegrino","year":"2014","unstructured":"Pellegrino A, Damiani GR, Strippoli D, Fantini F. Robotic transperitoneal ilioinguinal pelvic lymphadenectomy for high-risk melanoma: an update of 18-month follow-up. J Robot Surg. 2014;8(2):189\u201391. https:\/\/doi.org\/10.1007\/s11701-014-0457-0.","journal-title":"J Robot Surg."},{"issue":"1","key":"14834_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1308\/003588413X13511609955012","volume":"95","author":"ADMK Ross","year":"2013","unstructured":"Ross ADMK, Kumar P, Challacombe BJ, Dasgupta P, Geh JLC. The addition of the surgical robot to skin cancer management. Ann R Coll Surg Engl. 2013;95(1):70\u20132. https:\/\/doi.org\/10.1308\/003588413X13511609955012.","journal-title":"Ann R Coll Surg Engl."},{"issue":"4","key":"14834_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jamcollsurg.2015.12.033","volume":"222","author":"LA Dossett","year":"2016","unstructured":"Dossett LA, Castner NB, Pow-Sang JM, et al. Robotic-assisted transperitoneal pelvic lymphadenectomy for metastatic melanoma: early outcomes compared with open pelvic lymphadenectomy. J Am Coll Surg. 2016;222(4):702\u20139. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.12.033.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"14834_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"key":"14834_CR16","unstructured":"British Association of Urological Surgeons. Surgical Audit Projects: Grading of Surgical Complications. Accessed 19 Sept 2023. https:\/\/www.baus.org.uk\/patients\/surgical_outcomes\/grading_of_surgical_complications.aspx."},{"issue":"9","key":"14834_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","volume":"16","author":"MA Henderson","year":"2015","unstructured":"Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(15)00187-4.","journal-title":"Lancet Oncol."},{"key":"14834_CR18","unstructured":"American Society of Anesthesiologists. \u200bStatement on ASA Physical Status Classification System. Accessed September 19, 2023. https:\/\/www.asahq.org\/standards-and-practice-parameters\/statement-on-asa-physical-status-classification-system."},{"issue":"1","key":"14834_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jamcollsurg.2014.02.019","volume":"219","author":"ME Egger","year":"2014","unstructured":"Egger ME, Brown RE, Roach BA, et al. Addition of an Iliac\/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma. J Am Coll Surg. 2014;219(1):101\u20138. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.02.019.","journal-title":"J Am Coll Surg."},{"key":"14834_CR20","unstructured":"Australia and New Zealand Clinical Trials Rgistry. Evaluation of Groin Lymphadenectomy Extent For metastatic Melanoma (EAGLE FM). Accessed 19 Sept 2023. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12614000721606."},{"key":"14834_CR21","unstructured":"Mottet N, Cornford P, Bergh R van den, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Accessed 19 Sept 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment."},{"issue":"1","key":"14834_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","volume":"72","author":"N Fossati","year":"2017","unstructured":"Fossati N, Willemse PPM, Van den Broeck T, et al. The Benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol. 2017;72(1):84\u2013109. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.003.","journal-title":"Eur Urol."},{"issue":"9","key":"14834_CR23","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1245\/s10434-011-1755-7","volume":"18","author":"AJ Spillane","year":"2011","unstructured":"Spillane AJ, Haydu L, McMillan W, Stretch JR, Thompson JF. Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. Ann Surg Oncol. 2011;18(9):2521\u20138. https:\/\/doi.org\/10.1245\/s10434-011-1755-7.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"14834_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.eururo.2020.03.032","volume":"78","author":"A Mattei","year":"2020","unstructured":"Mattei A, W\u00fcrnschimmel C, Baumeister P, et al. Standardized and simplified robot-assisted superextended pelvic lymph node dissection for prostate cancer: the monoblock technique. Eur Urol. 2020;78(3):424\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.032.","journal-title":"Eur Urol."},{"issue":"1","key":"14834_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2013.03.057","volume":"65","author":"G Ploussard","year":"2014","unstructured":"Ploussard G, Briganti A, de la Taille A, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications\u2014a systematic review of the literature. Eur Urol. 2014;65(1):7\u201316. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.057.","journal-title":"Eur Urol."},{"key":"14834_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2022.04.002","volume":"167","author":"SB Goldenthal","year":"2022","unstructured":"Goldenthal SB, Reimers MA, Singhal U, et al. Prostate cancer with peritoneal carcinomatosis: a robotic-assisted radical prostatectomy-based case series. Urology. 2022;167:171\u20138. https:\/\/doi.org\/10.1016\/j.urology.2022.04.002.","journal-title":"Urology."},{"issue":"10","key":"14834_CR27","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1245\/s10434-007-9512-7","volume":"14","author":"B Badgwell","year":"2007","unstructured":"Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007;14(10):2867\u201375. https:\/\/doi.org\/10.1245\/s10434-007-9512-7.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"14834_CR28","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1016\/j.bjps.2021.03.115","volume":"74","author":"O Jones","year":"2021","unstructured":"Jones O, Murphy SH, Biosse-Duplan G, Patel AJK, Roshan A, Durrani AJ. Lymph node dissections in cutaneous malignancy: Where are we now? A review of 10 years\u2019 experience at a tertiary centre. J Plast Reconstr Aesthetic Surg. 2021;74(11):2993\u20138. https:\/\/doi.org\/10.1016\/j.bjps.2021.03.115.","journal-title":"J Plast Reconstr Aesthetic Surg."},{"key":"14834_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12364-9","author":"CE Sharon","year":"2022","unstructured":"Sharon CE, Straker RJ, Li EH, Karakousis GC, Miura JT. National practice patterns in the management of the regional lymph node basin after positive sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-12364-9.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"14834_CR30","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1245\/s10434-023-13935-0","volume":"30","author":"KE Rhodin","year":"2023","unstructured":"Rhodin KE, Jung SH, Elleson K, et al. Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter? Ann Surg Oncol. 2023;30(11):6340\u201352. https:\/\/doi.org\/10.1245\/s10434-023-13935-0.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"14834_CR31","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"24","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24(11):1655\u201361. https:\/\/doi.org\/10.1038\/s41591-018-0198-0.","journal-title":"Nat Med."},{"issue":"7","key":"14834_CR32","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(19)30151-2.","journal-title":"Lancet Oncol."},{"issue":"6","key":"14834_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388. https:\/\/doi.org\/10.1038\/s41591-022-01851-x.","journal-title":"Nat Med."},{"key":"14834_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.004","volume":"182","author":"ACJ van Akkooi","year":"2023","unstructured":"van Akkooi ACJ, Blank C, Eggermont AMM. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. Eur J Cancer. 2023;182:38\u201342. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.004.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14834-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14834-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:06:22Z","timestamp":1709424382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14834-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["14834"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14834-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"8 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AR is supported by a Cancer Research UK\/Royal College of Surgeons Clinician Scientist Fellowship (C64667\/A27958) and has received honoraria from the Alliance for Cancer Early Detection, and the British Association for Plastic, Reconstructive and Aesthetic Surgery. BWL received funding from Cancer Alliances and NHS England, honoraria for public speaking from Parsek, consultancy fees from Digital Surgery, MDOUTLOOK, honoraria from AstraZeneca and Astellas, and has a leadership role in the British Association of Urological Surgeons (Section of Oncology). AJD reports paid consultancy from Norgine BV. Other authors declare no conflicts of interest.AR had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Data partially presented as poster at the 49th British Association for Surgical Oncology (BASO) Annual Scientific Conference, London, United Kingdom, November 2022.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}